Health

Sustained, proactive, progressive and evidence-based strategies for effective surveillance, testing through expanded effective country-wide network of labs, coupled with Standard Treatment Protocol for ensuring effective clinical treatment of COVID19 cases have resulted in a progressive increase of 24,491 in COVID-19 recoveries during the last 24 hours. This has pushed the cumulative figure of recovered cases among COVID-19 patients to 7,24,577, as on date.

The focused efforts of Centre and State/UT governments on efficient clinical management of hospitalized cases have ensured that India’s Case Fatality Rate has fallen below 2.5%. With effective Containment Strategy, aggressive testing and standardized clinical management protocols based on holistic Standard of Care approach, the Case Fatality Rate has significantly dipped. The Case Fatality Rate is progressively falling and currently, it is 2.49%. India has one of the lowest fatality rates in the world.

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today launched the world’s first hypertension awareness symbol, in collaboration with Association of Physicians of India (API) and Hypertension Society of India (HSI). The symbol is developed in consultation with 50,000 leading doctors in the country, to raise awareness of the growing burden of hypertension and the need for timely screening.

Union Minister of Health and Family Welfare Dr. Harsh Vardhan, speaking on the success achieved by India on the Maternal Mortality Ratio (MMR), said, “Maternal Mortality Ratio (MMR) of India has declined by 9 points in one year as per the Special Bulletin on MMR released by the Registrar General of India. The ratio has declined from 122 in 2015-17 to 113 in 2016-18 (7.4 % decline).” He highlighted that the country has been witnessing a progressive reduction in MMR from 167 in 2011-2013, 130 in 2014-2016, 122 in 2015-17, and to 113 in 2016-18.

The ministry said the vaccine will be used for active immunisatiuon against invasive disease and pneumonia caused by ‘Streptococcus pneumonia’ among infants.

Human clinical trials for a vaccine for Covid-19 have been initiated in the country with approximately 1,000 volunteers participating in the exercise for each of the two indigenously developed vaccine candidates, the ICMR said on Tuesday.

India’s second possible vaccine against COVID-19, ZyCoV-D, is all set to begin its human trial this month, the company said. It plans to conduct the trials on 1,000 volunteers across multiple sites in the country. In last week of June 2020, Zydus Cadila group received approval from Drug Controller General of India (DGCI) to initiate phase 1 and phase 2 human clinical trials of possible COVID-19 vaccine in India.